Bioton hopes its investment will secure it 20% of the Russian insulin market

"The value of the investment amounts to $20 million. It will be financed jointly with our two Russian partners in the mode of joint venture," announced Adam Wilczęga, president of Bioton. He went on to say that Russia is the fifth largest market in the world, while its structure resembles the Polish market. In Q4 Bioton will begin to sell its insulin on the Russian market. "We want to make lower price our competitive advantage. We also expect that thanks to being an investor and local producer, we will become more competitive in state tenders," said Wilczęga. The Russian plant will also deliver products to Belarus and Ukraine where the company will compete with other foreign players. (Puls Biznesu, pp. 1, 7) M.M.